clinical trial · NCT06863961
A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis
Atopic DermatitisAfimkibartPlacebo
brief summary
The purpose of this study is to assess the efficacy and safety of Afimkibart (also known as RO7790121) in participants with moderate to severe atopic dermatitis (AD).
started
Apr 1, 2025
primary completion
Oct 5, 2026
completion
Apr 19, 2027
last updated
May 6, 2026
official title
A Phase II, Multicenter, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of RO7790121 in Patients With Moderate to Severe Atopic Dermatitis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol